India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to knowHims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and re...
Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo NordiskThe US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...
Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in IndiaNovo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...
Wegovy pill explained: Pricing, doses, and where to get Novo Nordisk's oral GLP-1 weight loss drugWegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...
Take a pill! Novo Nordisk's Wegovy gets US' nod as daily pill for obesity treatmentNovo Nordisk's popular weight-loss drug Wegovy is now available as a pill in the US. The US Food and Drug Administration has approved the o...
Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
Novo Nordisk launches limited offer: New patients can start Ozempic or Wegovy for $199 a monthNovo Nordisk is offering a new discount on its GLP-1 drugs Ozempic and Wegovy for a short time. The prices are lower for both new and exist...
Costco to sell Ozempic and Wegovy at huge discounts — even if you don’t have insuranceCostco offers huge Ozempic and Wegovy discounts. Members can save on these diabetes and weight loss medications. The program makes life-cha...
Drugmaker Novo Nordisk freezes hiring for non-critical jobsNovo Nordisk, the maker of Wegovy, has initiated a global hiring freeze for non-critical roles amid increasing competition and pressure fro...
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats upNovo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sa...
A big fat fight has just broken out in IndiaIndia's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gain...
Novo Nordisk readies to bring weight-loss drug Wegovy to IndiaDanish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...
Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...